Detalhe da pesquisa
1.
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
J Transl Med
; 17(1): 303, 2019 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31488153
2.
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
Lancet Oncol
; 18(4): 464-472, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28268064
3.
Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.
Mol Cancer Ther
; 22(7): 891-900, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37186518
4.
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
J Med Chem
; 64(1): 644-661, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356246
5.
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
J Med Chem
; 63(21): 12725-12747, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054210
6.
Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
Melanoma Res
; 29(1): 85-88, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30211812
7.
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer.
ACS Med Chem Lett
; 9(9): 861-863, 2018 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30258528
8.
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Melanoma Res
; 28(1): 65-70, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29227333
9.
Cyclization of the acyl glucuronide metabolite of a neutral endopeptidase inhibitor to an electrophilic glutarimide: synthesis, reactivity, and mechanistic analysis.
J Med Chem
; 50(24): 6165-76, 2007 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-17985860
10.
Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors.
Cell Chem Biol
; 24(11): 1388-1400.e7, 2017 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28965727
11.
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
J Med Chem
; 60(7): 3002-3019, 2017 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28287730
12.
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.
J Med Chem
; 49(14): 4409-24, 2006 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-16821800
13.
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
J Med Chem
; 59(5): 2005-24, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26756222
14.
Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
Mol Cancer Ther
; 11(1): 57-65, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22084163
15.
The discovery of small molecule inhibitors of neutral endopeptidase. Structure-activity studies on functionalized glutaramides.
Chem Biol Drug Des
; 67(1): 74-7, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16492151